Sano Chemicals Inc.

Sano Chemicals develops innovative therapeutic compounds to treat acute and chronic illnesses, focusing on fungal and bacterial infections. The company's lead assets include Occidiofungin for serious fungal infections and Mutacin for antibiotic-resistant bacteria.

Over 100 million women worldwide lack effective treatment options for recurrent vulvovaginal candidasis, while antibiotic resistant bacteria prevalence increases as antibiotic discovery rates decline.